Indivior Pharmaceuticals stock reports USD 8.13 special dividend

Indivior Pharmaceuticals stock was trading at USD 36.01 on Nasdaq on September 23, 2026 at 3:19 p.m. ET, down 0.50 percent for the session. The company has declared a USD 8.13 special dividend tied to the planned merger with Supernus Pharmaceuticals, according to Business Insider on September 17, 2026.

Dividend depends on merger closing

The special dividend is payable to holders of record on October 30, 2026, while payment is scheduled for November 6, 2026, subject to completion of the transaction. That structure makes the merger timetable a direct value driver for existing Indivior shareholders.

The planned transaction would combine Indivior's opioid use disorder portfolio with Supernus Pharmaceuticals. Indivior's board has linked the USD 8.13 distribution to the closing condition, so the payment and the corporate combination remain connected events.

Q2 revenue reached USD 343 million

Indivior reported USD 343 million in Q2 2026 revenue, up 13.6 percent from the prior year, while adjusted EPS rose 125.5 percent year over year to USD 1.15, according to Yahoo Finance on September 23, 2026.

Sublocade revenue contributed USD 253 million in the quarter, an increase of 21 percent from the prior year. The company also raised full year 2026 net revenue guidance to USD 1.295 billion-USD 1.365 billion from USD 1.215 billion-USD 1.285 billion.

Stock remains below yearly high

At USD 36.01, Indivior's Nasdaq price was 15.9 percent below its 52-week high of USD 42.81 and USD 13.46 above its 52-week low of USD 22.55 on September 23, 2026. The market capitalization was USD 4.493 billion at the same timestamp.

The figures frame the stock's near-term setup around two separate dates: the October 30 dividend record date and the November 6 payment date. For investors, the merger condition is the key distinction between the declared distribution and a completed cash payment.

Nasdaq price and investor calendar

Indivior Pharmaceuticals stock stood at USD 36.01 on Nasdaq on September 23, 2026 at 3:19 p.m. ET, with a daily change of negative 0.50 percent. The company is classified in Healthcare and Drug Manufacturers, Specialty and Generic.